AstraZeneca exceeded second-quarter 2026 profit expectations and reaffirmed its annual guidance.
Core earnings reached $2.63 per share, surpassing the $2.48 consensus estimate. Total revenue hit $15.38 billion, representing a 5% increase at constant exchange rates. Oncology and Rare Disease sales drove growth despite a slight revenue miss against forecasts.
Management expects full-year 2026 revenue to increase by a mid-to-high-single-digit percentage. Core earnings per share are projected to grow by a low double-digit percentage. The company increased its interim dividend by 3 cents.
This dividend hike signals management confidence despite recent clinical trial setbacks. AstraZeneca reiterated its goal to achieve $80 billion in total revenue by 2030. Shares rose approximately 1% in pre-market trading following the report.